AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00698100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human tyrosinase
Description: Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
Study NCT00698100 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mouse tyrosinase
Description: Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
Study NCT01963364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inulin challenge
Description: On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
Study NCT01963364 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: oligofructose supplement
Description: Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(\<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
Study NCT01893138 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo control is the vehicle solution used for the study product.
Study NCT01893138 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Iltamiocel
Description: AMDC is the study product (autologous muscle-derived cells). The generic name is iltamiocel. Single intraurethral injection of 150 x 10\^6 cells.
Study NCT02518230 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Neurally Adjusted Ventilatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
Study NCT02518230 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Synchronized Interm. Mandatory Assist
Description: The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
Study NCT03279939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Color Fundus Photography
Description: Non-contact white light photography.
Study NCT00928837 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Flavocoxid 500 mg
Description: flavonoid mixture
Study NCT00928837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen
Description: non-steroidal anti-inflammatory drug
Study NCT03279939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fluorescein Angiography
Description: An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of retinal vessels in two dimensional images.
Study NCT03279939 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Indocyaine Green Angiography
Description: An imaging procedure where dye is injected into a vein and images are taken of the back of the eye to visualize the perfusion of choroidal vessels in two dimensional images.
Study NCT00928837 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00928837 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: flavocoxid 250 mg
Description: Medical food product
Study NCT02154529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Study NCT02154529 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study NCT01524042 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pants for colonoscopy
Description: We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
Study NCT03502642 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)
Description: After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
Study NCT03502642 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: wound infusion (Dosi-Pain® Kit, LEVENTON SAU, Spain)
Description: After peritoneum closure a 16cm multiorifice perforated catheter (Dosi-Pain® Kit, LEVENTON SAU, Spain) was inserted by the surgeon below the fascia used for normal saline continuous infusion in the Placebo group and for continuous ropivacaine infusion (Ropivacaina Molteni®, MOLTENI FARMACEUTICI, Italy) in the ropivacaine group.
Study NCT03502642 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Spinal Anesthesia
Description: Cesarean section was conducted under spinal anesthesia in both groups
Study NCT03502642 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal Anesthesia
Description: Cesarean section was conducted under spinal anesthesia in both groups
Study NCT03502642 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: intrathecal morphine
Description: Intrathecal morphine was administered during spinal anesthesia in the placebo group but not in the ropivacaine group
Study NCT03502642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine (Ropivacaina Molteni®)
Description: A10ml bolus of ropivacaine 7.5mg/ml were administered in the wound catheter after skin closure then an infusion of ropivacaine 2mg/ml at the rate of 5ml/h was administered as wound infusion via the Dosi-Pain® Kit for 48hours.
Study NCT02721732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02721732 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT02721732 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01008787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Training
Description: In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
Study NCT01008787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
Study NCT01008787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
Study NCT01008787 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: PA Newsletter
Description: At Weeks 5 and 9, receive a physical activity (PA) newsletter.
Study NCT04270045 — intervention group
Intervention type: DEVICE
Intervention: Non-invasive forced airway oscillometry
Description: This non-invasive device will measure pulmonary mechanics in spontaneously breathing premature infants and term infants without pulmonary disease. Infant will be in supine position and breathing regularly. A cushioned mask will be placed on the infant's face, covering the nose and mouth. Measurements typically take less than 20 seconds and no more than 3 repetitions will be done at each time point.
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Given IV
Study NCT02950766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NeoVax
Description: combination of Neoantigen peptides and poly-ICLC
Study NCT02950766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: local administration of ipilimumab
Study NCT01344993 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MA09-hRPE
Description: Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin Hydrochloride
Description: Given IV
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Given IV
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study NCT03435952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: 200 mg by intravenous infusion starting on Day 0, and continuing every 3 weeks for up to 12 months.
Study NCT03435952 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clostridium Novyi-NT
Description: Participants given a single dose of Clostridium Novyi-NT by intratumoral injection on Day 8.~Clostridium Novyi-NT administered starting with Cohort 1 at a dose of 3 x 10\^4 spores followed by dose escalation.
Study NCT03435952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline
Description: Starting on Day 15, participant takes Doxycycline by mouth 2 times a day for the rest of participant's life to lower the risk of further growth of Clostridium novyi-NT
Study NCT03587662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib Citrate
Description: Given PO
Study NCT00811902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerispirdine
Description: tablet, oral administration
Study NCT00811902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: tablet, oral administration
Study NCT01868698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-voltage electrical stimulation
Study NCT01868698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy
Study NCT01868698 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: shortwave diathermy
Study NCT04280848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: UCPVax
Description: The UCPVax vaccination protocol will start at least one month after glioblastoma patients have completed the concomitant radiochemotherapy (Radiotherapy + Temozolomide RT/TMZ).~UCPVax vaccine will injected subcutaneously at days 1, 8, 15, 29, 36 and 43 (priming phase) following by boost vaccination one month after the last injection and then every 8 weeks for 12 months maximum.
Study NCT04280848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: 6 additional monthly cures of Temozolomide (after concomitant radiotherapy and temozolomide) according to standard of care
Study NCT05226806 — intervention group
Intervention type: OTHER
Intervention: Measurement of cardiorespiratory performance in 3 different settings
Description: The study is divided into three examinations days, which extend over a maximum of 2 weeks:~* Day 1: Inclusion examination, time required: 1.5 hours Taking anamnesis, medical examination and blood drawing, determination of PROCAM score, Framingham score, ESC score, anthropometric measurements, questionnaires (IPAQ-physical activity, health status / quality of life (SF 36)), pulmonary function test, resting ECG, echocardiography, heart rate variability measurement (VO2max determination), spiroergometry (modified Bruce protocol) on the treadmill incl. inquiries about the BORG scale~* Day 2: 1 km test trail, Time required: 1 hour: Completion of a 1 km cardio test path including mobile spiroergometry~* Day 3: 8 km hike, time required approx. 3.5 hours: Participation in a guided cardio hike over 8 km, if applicable, including spiroergometry Afterwards (In Austria only): Logging of physical activity, physical motivation and accompanying circumstances over a period of 3 weeks
Study NCT05226806 — intervention group
Intervention type: OTHER
Intervention: GENERAL CARDIO HIKES AS PART OF GENERAL TOURIST OFFER OF MUNICIPALITIES
Description: General cardio hikes (WITHOUT spirometric breathing gas analysis) on the selected hiking trails. Measurement of the heart rate as well as the route, time and walking speed using GPS geotracking using an anonymized user profile. User survey regarding the user-friendliness of the application.
Study NCT02216240 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paramedic
Study NCT02216240 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard care
Study NCT03395184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600 Placebo
Description: 12 weeks, followed by PF-06651600, 50 mg once daily (QD) for 52 weeks
Study NCT03395184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06651600
Description: 200 mg QD for 8 weeks, followed by 50 mg QD up to 56 weeks
Study NCT03286699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Intervention
Description: The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
Study NCT03395184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo PF-06700841
Description: 12 weeks, followed by PF-06700841, 30 mg QD for 52 weeks
Study NCT03395184 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06700841
Description: 60 mg QD for 12 weeks followed by 30 mg QD for up to 52 weeks
Study NCT00558220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Consolidation treatment part 1: HD-chemotherapy with ASCT
Description: Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.~High dose chemotherapy (HD-chemotherapy) consists of:~BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.~On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery.
Study NCT03286699 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Physical Activity Intervention
Description: The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (\~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (\~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
Study NCT00558220 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Consolidation treatment part 2: Radiotherapy
Description: Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
Study NCT01369706 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hand-held metal detector
Description: 2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
Study NCT01751451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
Study NCT01751451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate plus degarelix
Description: Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
Study NCT01751451 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
Study NCT04778683 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The investigator explained the use of VR glasses to the children in the VR group. The investigator selected two VR programs to be watched by the children. In the VR program named Amazon, the child perceives himself to be walking among the trees in the Amazon forests. The other VR program gives the child a feeling of water skiing. Before commencement of the study, the VR applications were administered to five children aged between five and ten years, and these children shared no negative feedback about the VR programs. Before the surgery, the children were allowed to watch the VR program of their choice, the average duration of which was 4.5 minutes, using the VR glasses. Parts of the device that come in contact with the children's faces were cleaned before each application
Study NCT01107353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Imipramine Pamoate
Description: 75 mg capsule
Study NCT02024399 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Strength training, aerobic exercise and core strengthening, running
Study NCT00462202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulodexide
Study NCT02843542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-MR
Description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
Study NCT02843542 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
Study NCT04385628 — intervention group
Intervention type: BEHAVIORAL
Intervention: the patient' relatives satisfaction questionnaire
Description: The patient' relatives satisfaction questionnaire will be filled face to face during informing the patient's relatives after the 3rd, 10th, and 30th days of patient admission, and once a month. We will evaluate the most recent questionnaire.
Study NCT04563871 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 80mg Osimertinib
Description: One tablet of 80mg Osimertinib for oral administration per day
Study NCT03551769 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tricaprilin
Description: Tricaprilin formulated as AC-SD-01
Study NCT01849146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adavosertib
Description: Given PO
Study NCT01849146 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT01849146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study NCT02667418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Fidaxomicin
Description: 200 mg PO twice daily for 10 days
Study NCT04330261 — intervention group
Intervention type: OTHER
Intervention: Exposure (not intervention) - SARS-CoV-2 infection
Description: Exposure is infection with the virus. There is no intervention
Study NCT02667418 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Vancomycin with Taper/Pulse
Description: 125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
Study NCT04127019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel chemotherapy (injection)
Study NCT04127019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel chemotherapy (injection)